ArticleAntimicrobial agents and chemotherapy2019
Molecular Epidemiology of Emerging Carbapenem Resistance in
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- Emergence ofMicrobiology spectrum · 2026Article
- Streamlining whole genome sequencing for clinical diagnostics with ONT technology.Scientific reports · 2025Article
- Identification and functional characterization of a novelFrontiers in cellular and infection microbiology · 2025Article
- Identification and characterisation of colistin-resistantNew microbes and new infections · 2024Article
- Correlation between the spread of IMP-producing bacteria and the promoter strength of blaThe Journal of antibiotics · 2024Article
- Identification and characterization of the capsule depolymerase Dpo27 from phage IME-Ap7 specific toFrontiers in cellular and infection microbiology · 2024Article
- Phylogenomics ofFrontiers in microbiology · 2023Article
- Mobile genetic elements in Acinetobacter antibiotic-resistance acquisition and dissemination.Annals of the New York Academy of Sciences · 2022Review
- Metagenomic Insights into Pathogenic Characterization of ST410Pathogens (Basel, Switzerland) · 2022Article
- Genetic Resistance Determinants in ClinicalAntibiotics (Basel, Switzerland) · 2022Article
- Synergism of imipenem with fosfomycin associated with the active cell wall recycling and heteroresistance in Acinetobacter calcoaceticus-baumannii complex.Scientific reports · 2022Article
- Ser253Leu substitution in PmrB contributes to colistin resistance in clinicalEmerging microbes & infections · 2021Article
- An Outbreak ofAntibiotics (Basel, Switzerland) · 2021Article
- In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan.The Journal of antimicrobial chemotherapy · 2021Article
- Article
- Genomic Characterization of Clinical Extensively Drug-ResistantMicroorganisms · 2021Article
- Emergence of ST63 Pandrug-ResistantFrontiers in cellular and infection microbiology · 2021Article
- AdeABC Efflux Pump Controlled by AdeRS Two Component System Conferring Resistance to Tigecycline, Omadacycline and Eravacycline in Clinical Carbapenem ResistantFrontiers in microbiology · 2020Article
- Coexistence ofFrontiers in microbiology · 2020Article
- Phenotypic Variation and Carbapenem Resistance Potential in OXA-499-ProducingFrontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the molecular epidemiology of carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.